학술논문
IT-Related Barriers and Facilitators to the Implementation of a New European eHealth Solution, the Digital Survivorship Passport (SurPass Version 2.0): Semistructured Digital Survey.
Document Type
Academic Journal
Author
de Beijer IAE; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; van den Oever SR; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Charalambous E; Health Level Seven Europe, Brussels, Belgium.; Venizeleio General Hospital of Heraklion, Heraklion, Greece.; Cangioli G; Health Level Seven Europe, Brussels, Belgium.; Balaguer J; Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Bardi E; St Anna Children's Hospital, Vienna, Austria.; Department of Paediatrics and Adolescent Medicine, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria.; Alfes M; Childhood Cancer International Europe, Vienna, Austria.; Cañete Nieto A; Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Correcher M; Instituto Investigación Sanitaria La Fe, Valencia, Spain.; Pinto da Costa T; Childhood Cancer International Europe, Vienna, Austria.; Degelsegger-Márquez A; Gesundheit Österreich GmbH, Vienna, Austria.; Düster V; Department of Studies and Statistics for Integrated Research and Projects, St Anna Children's Cancer Research Institute, Vienna, Austria.; Filbert AL; Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Grabow D; Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Gredinger G; Gesundheit Österreich GmbH, Vienna, Austria.; Gsell H; Childhood Cancer International Europe, Vienna, Austria.; Haupt R; Diagnosi, Osservazione, Prevenzione dopo trattamento Oncologico Clinic, Department of Hematology/Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina Gaslini, Genova, Italy.; van Helvoirt M; University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium.; Ladenstein R; St Anna Children's Hospital, Vienna, Austria.; Department of Studies and Statistics for Integrated Research and Projects, St Anna Children's Cancer Research Institute, Vienna, Austria.; Department of Paediatrics, Medical University of Vienna, Vienna, Austria.; Langer T; Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.; Laschkolnig A; Gesundheit Österreich GmbH, Vienna, Austria.; Muraca M; Diagnosi, Osservazione, Prevenzione dopo trattamento Oncologico Clinic, Department of Hematology/Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina Gaslini, Genova, Italy.; Pluijm SMF; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Rascon J; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.; Clinics for Children's Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.; Schreier G; Center for Health and Bioresources, Austrian Institute of Technology, Graz, Austria.; Tomášikova Z; Childhood Cancer International Europe, Vienna, Austria.; Trauner F; Gesundheit Österreich GmbH, Vienna, Austria.; Trinkūnas J; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.; Trunner K; Gesundheit Österreich GmbH, Vienna, Austria.; Uyttebroeck A; University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium.; Kremer LCM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands.; Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.; van der Pal HJH; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Chronaki C; Health Level Seven Europe, Brussels, Belgium.
Source
Publisher: JMIR Publications Country of Publication: Canada NLM ID: 100959882 Publication Model: Electronic Cited Medium: Internet ISSN: 1438-8871 (Electronic) Linking ISSN: 14388871 NLM ISO Abbreviation: J Med Internet Res Subsets: MEDLINE
Subject
Language
English
Abstract
Background: To overcome knowledge gaps and optimize long-term follow-up (LTFU) care for childhood cancer survivors, the concept of the Survivorship Passport (SurPass) has been invented. Within the European PanCareSurPass project, the semiautomated and interoperable SurPass (version 2.0) will be optimized, implemented, and evaluated at 6 LTFU care centers representing 6 European countries and 3 distinct health system scenarios: (1) national electronic health information systems (EHISs) in Austria and Lithuania, (2) regional or local EHISs in Italy and Spain, and (3) cancer registries or hospital-based EHISs in Belgium and Germany.
Objective: We aimed to identify and describe barriers and facilitators for SurPass (version 2.0) implementation concerning semiautomation of data input, interoperability, data protection, privacy, and cybersecurity.
Methods: IT specialists from the 6 LTFU care centers participated in a semistructured digital survey focusing on IT-related barriers and facilitators to SurPass (version 2.0) implementation. We used the fit-viability model to assess the compatibility and feasibility of integrating SurPass into existing EHISs.
Results: In total, 13/20 (65%) invited IT specialists participated. The main barriers and facilitators in all 3 health system scenarios related to semiautomated data input and interoperability included unaligned EHIS infrastructure and the use of interoperability frameworks and international coding systems. The main barriers and facilitators related to data protection or privacy and cybersecurity included pseudonymization of personal health data and data retention. According to the fit-viability model, the first health system scenario provides the best fit for SurPass implementation, followed by the second and third scenarios.
Conclusions: This study provides essential insights into the information and IT-related influencing factors that need to be considered when implementing the SurPass (version 2.0) in clinical practice. We recommend the adoption of Health Level Seven Fast Healthcare Interoperability Resources and data security measures such as encryption, pseudonymization, and multifactor authentication to protect personal health data where applicable. In sum, this study offers practical insights into integrating digital health solutions into existing EHISs.
(©Ismay A E de Beijer, Selina R van den Oever, Eliana Charalambous, Giorgio Cangioli, Julia Balaguer, Edit Bardi, Marie Alfes, Adela Cañete Nieto, Marisa Correcher, Tiago Pinto da Costa, Alexander Degelsegger-Márquez, Vanessa Düster, Anna-Liesa Filbert, Desiree Grabow, Gerald Gredinger, Hannah Gsell, Riccardo Haupt, Maria van Helvoirt, Ruth Ladenstein, Thorsten Langer, Anja Laschkolnig, Monica Muraca, Saskia M F Pluijm, Jelena Rascon, Günter Schreier, Zuzana Tomášikova, Florian Trauner, Justas Trinkūnas, Kathrin Trunner, Anne Uyttebroeck, Leontien C M Kremer, Helena J H van der Pal, Catherine Chronaki, PanCareSurPass Consortium. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 02.05.2024.)
Objective: We aimed to identify and describe barriers and facilitators for SurPass (version 2.0) implementation concerning semiautomation of data input, interoperability, data protection, privacy, and cybersecurity.
Methods: IT specialists from the 6 LTFU care centers participated in a semistructured digital survey focusing on IT-related barriers and facilitators to SurPass (version 2.0) implementation. We used the fit-viability model to assess the compatibility and feasibility of integrating SurPass into existing EHISs.
Results: In total, 13/20 (65%) invited IT specialists participated. The main barriers and facilitators in all 3 health system scenarios related to semiautomated data input and interoperability included unaligned EHIS infrastructure and the use of interoperability frameworks and international coding systems. The main barriers and facilitators related to data protection or privacy and cybersecurity included pseudonymization of personal health data and data retention. According to the fit-viability model, the first health system scenario provides the best fit for SurPass implementation, followed by the second and third scenarios.
Conclusions: This study provides essential insights into the information and IT-related influencing factors that need to be considered when implementing the SurPass (version 2.0) in clinical practice. We recommend the adoption of Health Level Seven Fast Healthcare Interoperability Resources and data security measures such as encryption, pseudonymization, and multifactor authentication to protect personal health data where applicable. In sum, this study offers practical insights into integrating digital health solutions into existing EHISs.
(©Ismay A E de Beijer, Selina R van den Oever, Eliana Charalambous, Giorgio Cangioli, Julia Balaguer, Edit Bardi, Marie Alfes, Adela Cañete Nieto, Marisa Correcher, Tiago Pinto da Costa, Alexander Degelsegger-Márquez, Vanessa Düster, Anna-Liesa Filbert, Desiree Grabow, Gerald Gredinger, Hannah Gsell, Riccardo Haupt, Maria van Helvoirt, Ruth Ladenstein, Thorsten Langer, Anja Laschkolnig, Monica Muraca, Saskia M F Pluijm, Jelena Rascon, Günter Schreier, Zuzana Tomášikova, Florian Trauner, Justas Trinkūnas, Kathrin Trunner, Anne Uyttebroeck, Leontien C M Kremer, Helena J H van der Pal, Catherine Chronaki, PanCareSurPass Consortium. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 02.05.2024.)